AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7922010 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffy coat preparation method with yield-enhancing change
Number of subjects: 29
Study 7922010 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous marrows purged with 4HC
Number of subjects: 29
Study 7922010 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic marrow infusion
Number of subjects: 29
Study 3049173 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 2% fenticonazole cream
Number of subjects: 41
Study 3049173 — intervention group
Group type: COMPARATOR
Intervention: Topical 1% bifonazole cream
Number of subjects: 41
Study 3049173 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall clinical evaluation
Number of subjects: 41
Study 3049173 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical significance
Number of subjects: 41
Study 11288030 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (NAL) infusion (1.6 mg/h for 2.5 hours) during GHRH testing
Number of subjects: 10
Study 11288030 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (1 microg/kg as an IV bolus)
Number of subjects: 10
Study 30411602 — intervention group
Group type: EXPERIMENTAL
Intervention: Power RMT (gradually increasing resistance)
Number of subjects: 13
Study 30411602 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance RMT (constant resistance)
Number of subjects: 13
Study 30411602 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 13
Study 30408100 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient reported outcome measures (PROMs)
Number of subjects: 0
Study 30408100 — intervention group
Group type: EXPERIMENTAL
Intervention: Tests of Eustachian tube (ET) opening including tympanometry, sonotubometry, and tubomanometry
Number of subjects: 0
Study 30408100 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tests of ET function
Number of subjects: 0
Study 30408100 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert panel diagnosis
Number of subjects: 0
Study 30408100 — intervention group
Group type: EXPERIMENTAL
Intervention: Index tests (14 tests of ET opening)
Number of subjects: 0
Study 27138896 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial blocker (BB)
Number of subjects: 40
Study 27138896 — intervention group
Group type: COMPARATOR
Intervention: Left double-lumen endotracheal tube (DL-ETT)
Number of subjects: 40
Study 25001158 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 0.5 mg bevacizumab
Number of subjects: 13
Study 25001158 — intervention group
Group type: COMPARATOR
Intervention: Conventional laser photoablation
Number of subjects: 13
Study 22469877 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror therapy program (25 mins, twice a day, five times a week, for 4 weeks)
Number of subjects: 26
Study 22469877 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror therapy program
Number of subjects: 26
Study 22469877 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation program (control group)
Number of subjects: 26
Study 19995097 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch (9.5 mg/24 h)
Number of subjects: 1195
Study 17567301 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene gel, 0.1% once daily (QD)
Number of subjects: 49
Study 17567301 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene gel, 0.1% every other day (QoD)
Number of subjects: 49
Study 17567301 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 49
Study 15692069 — intervention group
Group type: EXPERIMENTAL
Intervention: ABO-compatible platelets, stored for 48 hours or less, large doses of platelets
Number of subjects: 533
Study 15692069 — intervention group
Group type: EXPERIMENTAL
Intervention: UV-B or gamma irradiation
Number of subjects: 533
Study 15692069 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered apheresis platelets, increased dose of platelets transfused
Number of subjects: 533
Study 15692069 — intervention group
Group type: COMPARATOR
Intervention: Heparin administration, fever, bleeding, increasing number of platelet transfusions, increasing weight, at least 2 pregnancies, male gender
Number of subjects: 533
Study 15692069 — intervention group
Group type: COMPARATOR
Intervention: Lymphocytotoxic antibody positivity
Number of subjects: 533
Study 15692069 — intervention group
Group type: COMPARATOR
Intervention: None specified
Number of subjects: 533
Study 12200204 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise in bright light (group A)
Number of subjects: 80
Study 12200204 — intervention group
Group type: COMPARATOR
Intervention: Exercise in normal indoor illumination (group B)
Number of subjects: 80
Study 10068658 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34-selected peripheral blood progenitor cells
Number of subjects: 131
Study 10068658 — intervention group
Group type: COMPARATOR
Intervention: Unselected peripheral blood progenitor cells
Number of subjects: 131
Study 7751898 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (RA) 45 mg/m2 orally twice per day for 14 days (Cycle 1)
Number of subjects: 13
Study 7751898 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (RA) 45 mg/m2 orally twice per day for 14 days plus ketoconazole 400 mg orally for one dose, then 200 mg orally three times per day for 14 days (Cycle 2)
Number of subjects: 13
Study 7751898 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole administration
Number of subjects: 13
Study 7751898 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 13
Study 2185460 — intervention group
Group type: EXPERIMENTAL
Intervention: Active PEMT units
Number of subjects: 20
Study 2185460 — intervention group
Group type: COMPARATOR
Intervention: Facsimile placebo units
Number of subjects: 20
Study 2185460 — intervention group
Group type: EXPERIMENTAL
Intervention: Active PEMT units (after 3 weeks)
Number of subjects: 20
Study 2185460 — intervention group
Group type: COMPARATOR
Intervention: Facsimile placebo units (after 3 weeks)
Number of subjects: 20
Study 647198 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound drainage in clean surgical wounds
Number of subjects: 250
Study 647198 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound drainage in potentially contaminated wounds
Number of subjects: 250
Study 647198 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound drainage in frankly contaminated wounds
Number of subjects: 250
Study 647198 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of drains in contaminated wounds
Number of subjects: 250
Study 31913961 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild Cognitive Impairment (MCI) diagnosed according to Petersen criteria
Number of subjects: 1960
Study 31913961 — intervention group
Group type: EXPERIMENTAL
Intervention: Age increase
Number of subjects: 1960
Study 31913961 — intervention group
Group type: EXPERIMENTAL
Intervention: Education increase
Number of subjects: 1960
Study 31913961 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE-ε4 carriage
Number of subjects: 1960
Study 30957508 — intervention group
Group type: EXPERIMENTAL
Intervention: I-STAND intervention
Number of subjects: 60
Study 30957508 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 29029681 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard volitional help sheet (10 critical situations)
Number of subjects: 133
Study 29029681 — intervention group
Group type: EXPERIMENTAL
Intervention: Single situation volitional help sheet (1 generic situation)
Number of subjects: 133
Study 29029681 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no implementation intentions)
Number of subjects: 133
Study 27125966 — intervention group
Group type: EXPERIMENTAL
Intervention: FE75C
Number of subjects: 785
Study 27125966 — intervention group
Group type: COMPARATOR
Intervention: FE50C
Number of subjects: 785
Study 27125966 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Manipulation (HM; tamoxifen or LHRH agonists)
Number of subjects: 785
Study 27125966 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Manipulation (HM; tamoxifen or LHRH agonists) in ER+/unknown disease
Number of subjects: 785
Study 27125966 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment groups (FE50C-HM, FE50C+HM, FE75C-HM, FE75C+HM)
Number of subjects: 785
Study 23884688 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid search with minimized familiarity of targets (Experiment 1)
Number of subjects: 0
Study 23884688 — intervention group
Group type: EXPERIMENTAL
Intervention: Encouraged flexible retrieval of target information (Experiment 2)
Number of subjects: 0
Study 22296781 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (daily bedtime subcutaneous NPH insulin)
Number of subjects: 78
Study 22296781 — intervention group
Group type: COMPARATOR
Intervention: Usual care (oral hypoglycemic agents)
Number of subjects: 78
Study 22296781 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 78
Study 22296781 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 78
Study 20668324 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 2.4 g/day for 2 years
Number of subjects: 62
Study 20668324 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EPA treatment)
Number of subjects: 62
Study 17619859 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg rimonabant daily for 15 days
Number of subjects: 42
Study 17619859 — intervention group
Group type: COMPARATOR
Intervention: 90 mg rimonabant on day 15 after 14 days of placebo
Number of subjects: 42
Study 17619859 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 15 days
Number of subjects: 42
Study 16320974 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (8 to 16mg per day)
Number of subjects: 102
Study 16320974 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (8 to 16mg per day) with DASH diet
Number of subjects: 102
Study 16320974 — intervention group
Group type: COMPARATOR
Intervention: DASH diet
Number of subjects: 102
Study 16363278 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatility index (PI) assessed at the ankle arteries by colour Doppler ultrasonography
Number of subjects: 106
Study 16363278 — intervention group
Group type: COMPARATOR
Intervention: Ankle-brachial Doppler index
Number of subjects: 106
Study 16363278 — intervention group
Group type: COMPARATOR
Intervention: Systolic ankle pressure
Number of subjects: 106
Study 11573666 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil 20 microg combined with morphine 200 microg
Number of subjects: 15
Study 11573666 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil and morphine
Number of subjects: 15
Study 11573666 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 15
Study 9757882 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic methotrexate therapy
Number of subjects: 80
Study 9757882 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic salpingostomy
Number of subjects: 80
Study 7841891 — intervention group
Group type: EXPERIMENTAL
Intervention: Group rehabilitation programme (four 3-hour sessions per week)
Number of subjects: 12
Study 7841891 — intervention group
Group type: EXPERIMENTAL
Intervention: Group rehabilitation programme
Number of subjects: 12
Study 7841891 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12
Study 7841891 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 12
Study 3340423 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitation of the release of constrained and overcontrolled negative affect
Number of subjects: 18
Study 3340423 — intervention group
Group type: COMPARATOR
Intervention: Information about pain and depression
Number of subjects: 18
Study 29866192 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 680
Study 29866192 — intervention group
Group type: COMPARATOR
Intervention: Amodiaquine-artesunate (AQAS)
Number of subjects: 680
Study 28689102 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (1 dose of 1 g IV) once a month for 12 months
Number of subjects: 103
Study 25142619 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-Based Treatment (FBT)
Number of subjects: 45
Study 25142619 — intervention group
Group type: COMPARATOR
Intervention: Systemic Family Therapy (alternate form)
Number of subjects: 45
Study 23973699 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES)
Number of subjects: 650
Study 23973699 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 650
Study 21483712 — intervention group
Group type: EXPERIMENTAL
Intervention: Full intervention (evidence‐based guidelines, training, job aides, local facilitation, supervision, and face‐to‐face feedback)
Number of subjects: 8
Study 21483712 — intervention group
Group type: EXPERIMENTAL
Intervention: Full intervention
Number of subjects: 8
Study 21483712 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (guidelines, didactic training, job aides, and written feedback)
Number of subjects: 8
Study 21483712 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 8
Study 18582947 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (ascorbic acid)
Number of subjects: 0
Study 16817042 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification with polyacrylic intraocular lens (IOL) implantation
Number of subjects: 20
Study 16817042 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 20
Study 12756354 — intervention group
Group type: COMPARATOR
Intervention: Normal values (healthy subjects)
Number of subjects: 0
Study 12756354 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age group (>70 years)
Number of subjects: 0
Study 12756354 — intervention group
Group type: EXPERIMENTAL
Intervention: Asian subjects
Number of subjects: 0
Study 12756354 — intervention group
Group type: EXPERIMENTAL
Intervention: African American subjects
Number of subjects: 0
Study 12756354 — intervention group
Group type: EXPERIMENTAL
Intervention: Legs with venous obstructive disease (with trophic changes)
Number of subjects: 0
Study 11008917 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived absolute risk of breast cancer
Number of subjects: 581
Study 11008917 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived comparative risk of breast cancer
Number of subjects: 581
Study 8943170 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) 1750 anti-Xa IU daily
Number of subjects: 1351
Study 8943170 — intervention group
Group type: COMPARATOR
Intervention: Standard unfractionated heparin (UFH) 5000 IU twice a day
Number of subjects: 1351
Study 1586105 — intervention group
Group type: EXPERIMENTAL
Intervention: Nal‐Glu (GnRH antagonist) for 6 weeks
Number of subjects: 15
Study 1586105 — intervention group
Group type: COMPARATOR
Intervention: Nal‐Glu plus testosterone enanthate (100 mg/wk)
Number of subjects: 15
Study 1586105 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 15
Study 4026044 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine 50 mg orally twice a day for 14 days
Number of subjects: 9
Study 31783900 — intervention group
Group type: EXPERIMENTAL
Intervention: STAR program (Sepsis Transition and Recovery program)
Number of subjects: 708
Study 31783900 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 708
Study 28760512 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-rated EQ-VAS scores <50
Number of subjects: 330
Study 28760512 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-rated EQ-VAS scores between 50 and 64
Number of subjects: 330
Study 28760512 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-rated EQ-VAS scores between 65 and 79
Number of subjects: 330
Study 28760512 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rated EQ-VAS
Number of subjects: 330
Study 26595549 — intervention group
Group type: EXPERIMENTAL
Intervention: SRT2104 50 mg daily
Number of subjects: 26
Study 26595549 — intervention group
Group type: EXPERIMENTAL
Intervention: SRT2104 500 mg daily
Number of subjects: 26
Study 26595549 — intervention group
Group type: EXPERIMENTAL
Intervention: SRT2104 (both doses)
Number of subjects: 26
Study 24134594 — intervention group
Group type: EXPERIMENTAL
Intervention: Client motivational language (arguments for and against change) during CBT sessions.
Number of subjects: 0
Study 21898014 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined thoracoscopic-laparoscopic esophagectomy (TLE)
Number of subjects: 185
Study 21898014 — intervention group
Group type: COMPARATOR
Intervention: Thoracoscopic esophagectomy (TE)
Number of subjects: 185
Study 21898014 — intervention group
Group type: COMPARATOR
Intervention: Open esophagectomy (OE)
Number of subjects: 185
Study 20368196 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified glucose control based on insulin (I-group)
Number of subjects: 93
Study 20368196 — intervention group
Group type: COMPARATOR
Intervention: Ongoing glucose-lowering treatment (C-group)
Number of subjects: 93
Study 17990195 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR-5 extract (340 mg/day)
Number of subjects: 89
Study 17990195 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR-5 extract (680 mg/day)
Number of subjects: 89
Study 17990195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 16167227 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal decompression after operation
Number of subjects: 368
Study 16167227 — intervention group
Group type: COMPARATOR
Intervention: No gastrointestinal decompression after operation
Number of subjects: 368
Study 12740266 — intervention group
Group type: EXPERIMENTAL
Intervention: IV tobramycin and ceftazidime
Number of subjects: 262
Study 10036845 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco cessation services (TCS) offered by dental offices
Number of subjects: 3088
Study 10036845 — intervention group
Group type: EXPERIMENTAL
Intervention: Interest in quitting tobacco
Number of subjects: 3088
Study 10036845 — intervention group
Group type: COMPARATOR
Intervention: Dentists' perception of patient expectations for TCS
Number of subjects: 3088
Study 10036845 — intervention group
Group type: COMPARATOR
Intervention: Barriers to providing TCS as reported by dentists
Number of subjects: 3088
Study 7793595 — intervention group
Group type: EXPERIMENTAL
Intervention: Homemade force pressure transducer
Number of subjects: 20
Study 7793595 — intervention group
Group type: COMPARATOR
Intervention: Commercially available accelerometer
Number of subjects: 20
Study 1922220 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of aspirin
Number of subjects: 3131
Study 1922220 — intervention group
Group type: COMPARATOR
Intervention: 283 mg of aspirin
Number of subjects: 3131
Study 7349618 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 0
Study 7349618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6420959 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (instead of steroids) with azathioprine and ATGAM for three months
Number of subjects: 33
Study 6420959 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine, high doses of prednisolone, and ATGAM for three months
Number of subjects: 33
Study 6420959 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (Ibuprofen)
Number of subjects: 33
Study 6420959 — intervention group
Group type: COMPARATOR
Intervention: Control group (steroids)
Number of subjects: 33
Study 6420959 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 33
Study 31006972 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonophoresis of piroxicam (PH-P)
Number of subjects: 33
Study 31006972 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonophoresis of dexamethasone sodium phosphate (PH-Dex)
Number of subjects: 33
Study 31006972 — intervention group
Group type: COMPARATOR
Intervention: Nondrug ultrasound (US) therapy
Number of subjects: 33
Study 28673117 — intervention group
Group type: EXPERIMENTAL
Intervention: Social robot intervention for teaching gesture recognition and production
Number of subjects: 13
Study 28673117 — intervention group
Group type: EXPERIMENTAL
Intervention: Social robot intervention for teaching gesture recognition
Number of subjects: 13
Study 28673117 — intervention group
Group type: EXPERIMENTAL
Intervention: Social robot intervention for teaching gesture production
Number of subjects: 13
Study 28673117 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 13
Study 27043932 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐glucan
Number of subjects: 69
Study 27043932 — intervention group
Group type: COMPARATOR
Intervention: Control (no β‐glucan)
Number of subjects: 69
Study 25480588 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin plus 75‐100 mg aspirin
Number of subjects: 1016
Study 25480588 — intervention group
Group type: COMPARATOR
Intervention: Warfarin only
Number of subjects: 1016
Study 21771042 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training programme (listening to a 13-minute relaxation programme daily)
Number of subjects: 129
Study 21771042 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training programme
Number of subjects: 129
Study 21771042 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 129
Study 20464781 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (HYPO group; esophageal temperature 32-33 degrees C) for 24 hours
Number of subjects: 16
Study 20464781 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (NORMO group; 36.5-37.5 degrees C) for 24 hours
Number of subjects: 16
Study 18185146 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein administration
Number of subjects: 39
Study 18185146 — intervention group
Group type: COMPARATOR
Intervention: Cystoid macular edema (CME) presence
Number of subjects: 39
Study 18185146 — intervention group
Group type: COMPARATOR
Intervention: Visual acuity (VA) assessment
Number of subjects: 39
Study 18185146 — intervention group
Group type: COMPARATOR
Intervention: Retinal thickness measurement
Number of subjects: 39
Study 15865225 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-IFN 1.5 microg/kg/week plus RBV 400 mg twice daily (arm A)
Number of subjects: 135